Improving Outcomes: A Genomically Targeted Approach to Cognition and Longevity
HTML-код
- Опубликовано: 31 июл 2023
- In this webinar, Drs. Sharon Hausman-Cohen, and Dale Bredesen will talk about how genomics has evolved to become a valuable tool that can help identify contributing factors to cognitive decline that otherwise would be difficult to detect including various sources of brain ischemia and how these different genomic factors can be addressed as part of a precision brain plan.
Additionally, they will talk about the intersection between brain health and longevity as they discuss Klotho, mTOR, and glutathione peroxidase. Come join this amazing presentation and discussion and deepen your knowledge of genomics and your ability to treat patients with concerns of cognition and aging.
For our friends outside the USA, note that IntellxxDNA will be available in Australia, EU, UK, Canada, and a few other countries starting in 2024.
Here is a list of the urls that are in QR code form in the presentation:
IntellxxDNA Learn More and Schedule a Private Tour (mention this webinar) - www.intellxxdna.com/demo/
ReCODE 2.0 Training for Practitioners - www.apollohealthco.com/practi...
KetoFLEX 12/3 Meal Delivery Service - ketoflex.apollohealthco.com
ReCODE Type 3 Toxic supplement - recodesupport.com/product/typ...
Astaxanthin supplement - lifeseasons.com/product/agele...
More Information on NeuroQ Supplements - neuroq.com
More Information on ReCODE Supplements - recodesupport.com 
Наука
OMG! This is priceless information. Thank you both for this valuable exchange.
very interesting information!!
Great information! Thank You! Where to order the Intellxx DNA for patients in Europe?
Hello, it is not yet available in Europe. However, if you reach out to them directly, they can put you on the list to be notified when it is available. You should be able to use this link: www.intellxxdna.com/contact/
Is there a possibility to add raw genetic data done on another platform to intellX to get the insights and recommendations?
No. We do need to repeat the genomics but it is a simple cheek swab. Many direct to consumer companies do not validate their data. That is why some do not report on Apo E2 for example and we want to make sure your physician is using correcct information in their decision making.
This discussion appears to be aimed at people with a medical background. It isn't helpful for a patient with Apo3/4 to listen to. We haven't read in your books anything that relates to these concepts.